Sugi Predict

Sugi Predict / Targets / CDC45

CDC45

Cell division control protein 45 homolog · O75419 · CDC45 on Sugi Atlas →

1,974 patent compounds predicted against CDC45, 1,715 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL13521609 SCHEMBL13521609 0.57 2/20
SCHEMBL8101065 SCHEMBL8101065 0.53 2/20
SCHEMBL14645035 SCHEMBL14645035 0.47 2/20
SCHEMBL13521649 SCHEMBL13521649 0.43 2/20
SCHEMBL14112723 SCHEMBL14112723 0.41 2/20
Molibresib Molibresib (SCHEMBL1872390) 1.00 1/20
Molibresib Molibresib (SCHEMBL12671490) 1.00 1/20
Molibresib Molibresib (SCHEMBL12966358) 1.00 1/20
SCHEMBL9998851 SCHEMBL9998851 0.91 1/20
SCHEMBL14756282 SCHEMBL14756282 0.88 1/20
SCHEMBL15980874 SCHEMBL15980874 0.88 1/20
SCHEMBL12966165 SCHEMBL12966165 0.87 1/20
SCHEMBL14756215 SCHEMBL14756215 0.87 1/20
SCHEMBL14756339 SCHEMBL14756339 0.87 1/20
SCHEMBL15980861 SCHEMBL15980861 0.87 1/20
SCHEMBL9998825 SCHEMBL9998825 0.86 1/20
SCHEMBL15980803 SCHEMBL15980803 0.86 1/20
SCHEMBL1874116 SCHEMBL1874116 0.85 1/20
SCHEMBL12671221 SCHEMBL12671221 0.85 1/20
SCHEMBL14756021 SCHEMBL14756021 0.85 1/20

Clinical trials — most relevant to CDC45 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Novel Peptide Vaccination for Patients With Advanced Prostate Cancer PHASE1/PHASE2UNKNOWN
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 PHASE1/PHASE2COMPLETED
Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery PHASE2COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Abemaciclib With or Without Atezolizumab for mCRPC PHASE2COMPLETED
INCB018424 in Patients With Advanced Hematologic Malignancies PHASE2COMPLETED
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma PHASE1WITHDRAWN
Nucleoside Therapy in Patients With Telomere Biology Disorders PHASE1RECRUITING
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Unusual Infiltrative Patterns of Malignant Cells in Endometrial Carcinoma and Immunohistochemical Expression of P53 nanUNKNOWN
Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals nanUNKNOWN
Hereditary Nonpolyposis Colorectal Cancer in Taiwan-Related Genetic Study and Clinical Applications nanUNKNOWN
Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma nanUNKNOWN
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants nanRECRUITING
PCD New Gene Discovery nanCOMPLETED
S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia nanCOMPLETED
Prospective Genetic Study in Patients With Ovarian Insufficiency nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Immunogenetics of Visceral Leishmaniasis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CDC45 binder may also engage these)

ProteinNameSimilarity
Q9Z1X9 — 0.999 Q9Z1X9 →
Q9YHZ6 — 0.998 Q9YHZ6 →
A7SBF0 — 0.984 A7SBF0 →
Q9M2Q4 — 0.982 Q9M2Q4 →
Q66I84 — 0.981 Q66I84 →
Q8BTZ4 — 0.981 Q8BTZ4 →
Q91YM2 — 0.980 Q91YM2 →
Q5ZLW3 — 0.980 Q5ZLW3 →
Q86TV6 — 0.979 Q86TV6 →
Q6PD82 — 0.979 Q6PD82 →
Q8IWV7 — 0.979 Q8IWV7 →
A8WE67 — 0.979 A8WE67 →
O35638 — 0.979 O35638 →
Q9WVK4 — 0.979 Q9WVK4 →
A5PKG6 — 0.979 A5PKG6 →
Q96Q05 — 0.979 Q96Q05 →
O55081 — 0.979 O55081 →
Q7RTS9 — 0.978 Q7RTS9 →
Q16K67 — 0.978 Q16K67 →
Q28ES8 — 0.978 Q28ES8 →
Q6TNR1 — 0.978 Q6TNR1 →
Q9D3E6 — 0.978 Q9D3E6 →
Q5RAW5 — 0.978 Q5RAW5 →
Q9VX32 — 0.978 Q9VX32 →
Q8WVM7 — 0.978 Q8WVM7 →
O74113 — 0.978 O74113 →
Q5R981 — 0.978 Q5R981 →
B3MET8 — 0.978 B3MET8 →
Q28IV6 — 0.978 Q28IV6 →
Q5E9R3 — 0.978 Q5E9R3 →